1. < Home

cardiomyopathy

SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction

Avula V, Sharma G, Kosiborod MN, Vaduganathan M, Neilan TG, Lopez T, Dent S, Baldassarre L, Scherrer-Crosbie M, Barac A, Liu J, Deswal A, Khadke[...]

By sjmartinez • October 29, 2023
Rare Variant Genetics and Dilated Cardiomyopathy Severity: The DCM Precision Medicine Study

Hofmeyer M, Haas GJ, Jordan E, Cao J, Kransdorf E, Ewald GA, Morris AA, Owens A, Lowes B, Stoller D, Wilson Tang WH, Garg S,[...]

By sjmartinez • August 29, 2023
Effectiveness of the Family Heart Talk Communication Tool in Improving Family Member Screening for Dilated Cardiomyopathy: Results of a Randomized Trial

Kinnamon DD, Jordan E, Haas GJ, Hofmeyer M, Kransdorf E, Ewald GA, Morris AA, Owens A, Lowes B, Stoller D, Wilson Tang WH, Garg S,[...]

By sjmartinez • March 21, 2023
Sudden cardiac death in the young: A consensus statement on recommended practices for cardiac examination by pathologists from the Society for Cardiovascular Pathology

Kelly KL, Lin PT, Basso C, Bois M, Buja LM, Cohle SD, d'Amati G, Duncanson E, Fallon JT, Firchau D, Fishbein G, Giordano C, Leduc[...]

By sjmartinez • February 4, 2023
Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer

Ganatra S, Dani SS, Yang EH, Zaha VG, Nohria A. Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer. JACC CardioOncol. 2022 Dec 20;4(5):616-623. doi: 10.1016/j.jaccao.2022.07.014. PMID: 36636447; PMCID:[...]

By sjmartinez • January 14, 2023
Novel Therapeutics for Anthracycline Induced Cardiotoxicity

Vuong JT, Stein-Merlob AF, Cheng RK, Yang EH. Novel Therapeutics for Anthracycline Induced Cardiotoxicity. Front Cardiovasc Med. 2022 Apr 22;9:863314. doi: 10.3389/fcvm.2022.863314. PMID: 35528842; PMCID:[...]

By rosaguerrero • May 9, 2022